TSHA — Taysha Gene Therapies Inc

Ownership history in Siren, L.L.C.  ·  6 quarters on record

This page tracks every 13F SEC filing in which Siren, L.L.C. reported a position in Taysha Gene Therapies Inc (TSHA). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
1.66% (2025 Q4)
Avg. % of fund
0.98%
First filed
2024 Q3
Last filed
2025 Q4
Quarters held
6
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 REDUCED 10,129,913 -884,824 -8.0% 1.66% $55.7M $5.50
2025 Q3 UNCHANGED 11,014,737 — 0% 1.41% $36.0M $3.27
2025 Q2 ADDED 11,014,737 +4,500,000 +69.1% 1.32% $25.4M $2.31
2025 Q1 REDUCED 6,514,737 -87,738 -1.3% 0.52% $9.1M $1.39
2 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    TSHA price (monthly, adj. close)

Other funds also holding TSHA

As of 2025 Q4 — sorted by position size

B Group, Inc. 7.31% Octagon Capital Advisors LP 3Y 5.92% GordonMD Global Investments LP 5.25% SUPERSTRING CAPITAL MANAGEMENT LP 2.89% Ally Bridge Group (NY) LLC 3Y 2.86% Ally Bridge Group (NY) LLC 3Y 2.62% Vestal Point Capital, LP 2.57% ACUTA CAPITAL PARTNERS, LLC 3Y 7Y 1.7% RA CAPITAL MANAGEMENT, L.P. 3Y 7Y 1.33% Quantum Private Wealth, LLC 3Y 1.32%
← Back to Siren, L.L.C. Holdings